Ajabnoor Ghada, Eldakhakhny Basmah, Hashim Kamal T, Alzahrani Mohammed M, Eskandarani Rayan, AlQusaibi Bader, Alqarni Ahmad K, Alsulaimani Naser M, Dahlan Mansour, Enani Sumia, Almoghrabi Yousef, Alamoudi Aliaa A, Alhozali Amani, Elsamanoudy Ayman
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU.
Food, Nutrition, and Lifestyle Research Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, SAU.
Cureus. 2023 Sep 11;15(9):e45055. doi: 10.7759/cureus.45055. eCollection 2023 Sep.
Laxatives are over-the-counter medications used as a treatment for constipation. The lipid-lowering effect of the long-term use of laxatives has been proposed.
To investigate the possible impact of the chronic use of laxatives on serum lipid profile, body mass index (BMI), and hemoglobin A1c (HbA1c).
An observational retrospective cohort study was conducted to analyze data related to patients who received laxatives for six or 12 months or more in the KAUH database system. BMI, weight, cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and HbA1c data were collected retrospectively from hospital records for three time points: baseline, six months, and 12 months of laxative treatment from the starting date for each patient.
A total of 106 patients' records fulfilled the inclusion criteria, 46 (43%) males with a mean age of 66 and 60 (57%) females with a mean age of 63. A significant decrease in plasma cholesterol and low-density lipoprotein-cholesterol (LDL-C) levels was observed in those who used laxatives for 12 months. Furthermore, an overall BMI and ALT reduction was seen in the combined. On the other hand, HbA1c levels appeared to improve in the combined group but not statistically significant. The change in the cholesterol level could be observed in patients receiving statin treatment and those without, with no statistical significance between the two groups.
Chronic laxative use for 12 months or more is associated with a decreased total and LDL-C level with no significant effect on high-density lipoprotein-cholesterol (HDL-C) levels. Additionally, there was a significant reduction in BMI and ALT. This effect is more prominent with combined therapy. Further multicentric studies on larger sample sizes are recommended to confirm our findings.
泻药是用于治疗便秘的非处方药物。长期使用泻药的降脂作用已被提出。
探讨长期使用泻药对血清脂质谱、体重指数（BMI）和糖化血红蛋白（HbA1c）的可能影响。
进行了一项观察性回顾性队列研究，以分析在KAUH数据库系统中接受泻药治疗6个月或12个月及以上的患者的数据。回顾性收集了每位患者从泻药治疗开始日期起的三个时间点（基线、6个月和12个月）的医院记录中的BMI、体重、胆固醇、甘油三酯、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）和HbA1c数据。
共有106例患者的记录符合纳入标准，其中46例（43%）为男性，平均年龄66岁，60例（57%）为女性，平均年龄63岁。使用泻药12个月的患者血浆胆固醇和低密度脂蛋白胆固醇（LDL-C）水平显著降低。此外，联合组的总体BMI和ALT有所降低。另一方面，联合组的HbA1c水平似乎有所改善，但无统计学意义。接受他汀类药物治疗的患者和未接受他汀类药物治疗的患者均可观察到胆固醇水平的变化，两组之间无统计学差异。
长期使用泻药12个月或更长时间与总胆固醇和LDL-C水平降低相关，对高密度脂蛋白胆固醇（HDL-C）水平无显著影响。此外，BMI和ALT显著降低。联合治疗时这种效果更显著。建议进行更多更大样本量的多中心研究以证实我们的发现。
